Patents by Inventor Hsin-Pai LI

Hsin-Pai LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for evaluating whether an individual with cancer is suitable for treatment with a CDK inhibitor
    Patent number: 11761044
    Abstract: The disclosure provides a method for evaluating whether an individual with cancer is suitable for being administered with anti-cancer drugs. Wherein the anti-cancer drug is a CDK inhibitor. The method includes the following steps: (1) detecting a copy number of a first gene and a copy number of a second gene from an in vitro sample of the individual with the cancer to obtain a copy number variation (CNV) of the first gene and a copy number variation (CNV) of the second gene; (2) calculating a copy number variation ratio (CNV ratio) between the copy number variation (CNV) of the first gene and the copy number variation (CNV) of the second gene, wherein the first gene encodes a cyclin and the second gene encodes a cyclin dependent kinase inhibitor (CDKN); and (3) determining whether the individual with the cancer is suitable for being administered with the CDK inhibitor according to the CNV ratio.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: September 19, 2023
    Assignees: CHANELUN IVERSITY, CHANG GUNG MEMORIAL HOSPITAL, LINKOU
    Inventors: Hsin-Pai Li, Cheng-Lung Hsu
  • METHOD FOR EVALUATING WHETHER AN INDIVIDUAL WITH CANCER SUITABLE FOR BEING ADMINISTERED WITH ANTI-CANCER DRUGS, METHOD FOR TREATING AN INDIVIDUAL WITH CANCER AND BIOMARKER IN A SAMPLE OF AN INDIVIDUAL WITH CANCER FOR MANUFACTURING A DIAGNOSIS COMBINATION
    Publication number: 20200010902
    Abstract: The disclosure provides a method for evaluating whether an individual with cancer is suitable for being administered with anti-cancer drugs. Wherein the anti-cancer drug is a CDK inhibitor. The method includes the following steps: (1) detecting a copy number of a first gene and a copy number of a second gene from an in vitro sample of the individual with the cancer to obtain a copy number variation (CNV) of the first gene and a copy number variation (CNV) of the second gene; (2) calculating a copy number variation ratio (CNV ratio) between the copy number variation (CNV) of the first gene and the copy number variation (CNV) of the second gene, wherein the first gene encodes a cyclin and the second gene encodes a cyclin dependent kinase inhibitor (CDKN); and (3) determining whether the individual with the cancer is suitable for being administered with the CDK inhibitor according to the CNV ratio.
    Type: Application
    Filed: June 25, 2019
    Publication date: January 9, 2020
    Inventors: Hsin-Pai LI, Cheng-Lung HSU